Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Personal Products Industry Analysis

UpdatedJun 30, 2026
DataAggregated Company Financials
Companies108
  • 7D1.8%
  • 3M9.6%
  • 1Y-17.1%
  • YTD-10.0%

Over the last 7 days, the Personal Products industry has risen 1.8%, driven by gains from Kenvue of 6.8%. Meanwhile, Estée Lauder Companies actually underperformed within the industry, shrinking 6.1% in the last week. In the past year, the industry is down 17%. As for the next few years, earnings are expected to grow by 32% per annum.

Industry Valuation and Performance

Has the U.S. Personal Products Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 30 Jun 2026US$84.1bUS$48.3bUS$693.8m17.2x121.2x1.7x
Thu, 28 May 2026US$80.2bUS$48.4bUS$745.2m17.7x107.7x1.7x
Sat, 25 Apr 2026US$78.2bUS$48.1bUS$614.7m22.8x127.2x1.6x
Mon, 23 Mar 2026US$80.7bUS$48.2bUS$678.5m21.5x118.9x1.7x
Wed, 18 Feb 2026US$93.8bUS$48.0bUS$846.4m22.2x110.8x2x
Fri, 16 Jan 2026US$94.6bUS$47.6bUS$350.2m22.4x270.1x2x
Sun, 14 Dec 2025US$90.0bUS$47.6bUS$351.1m23.2x256.2x1.9x
Tue, 11 Nov 2025US$83.2bUS$47.5bUS$491.9m21.3x169.1x1.8x
Thu, 09 Oct 2025US$90.8bUS$47.7bUS$307.8m20.3x295.1x1.9x
Sat, 06 Sep 2025US$99.4bUS$47.6bUS$304.2m22.3x326.6x2.1x
Mon, 04 Aug 2025US$100.6bUS$48.1bUS$113.4m19.8x887.4x2.1x
Wed, 02 Jul 2025US$96.8bUS$48.0bUS$109.4m18x885.2x2x
Fri, 30 May 2025US$95.3bUS$48.0bUS$128.1m21.8x743.5x2x
Sun, 27 Apr 2025US$86.8bUS$48.7bUS$549.8m21.2x157.9x1.8x
Tue, 25 Mar 2025US$91.0bUS$48.7bUS$378.1m28.3x240.6x1.9x
Thu, 20 Feb 2025US$90.8bUS$49.0bUS$336.6m24.6x269.8x1.9x
Sat, 18 Jan 2025US$98.5bUS$49.3bUS$1.5b26.8x66.7x2x
Mon, 16 Dec 2024US$103.5bUS$49.3bUS$1.5b29.1x70x2.1x
Wed, 13 Nov 2024US$99.7bUS$49.3bUS$1.5b26.8x67.8x2x
Fri, 11 Oct 2024US$105.7bUS$49.5bUS$1.6b25.6x65.3x2.1x
Sun, 08 Sep 2024US$107.3bUS$49.5bUS$1.6b20.8x65.5x2.2x
Tue, 06 Aug 2024US$105.2bUS$48.9bUS$2.5b22.4x42.6x2.2x
Thu, 04 Jul 2024US$112.9bUS$49.0bUS$2.4b20.8x46.6x2.3x
Sat, 01 Jun 2024US$114.9bUS$49.0bUS$2.4b21.8x47.4x2.3x
Mon, 29 Apr 2024US$125.7bUS$48.8bUS$2.5b24.6x49.5x2.6x
Wed, 27 Mar 2024US$129.1bUS$48.8bUS$2.5b25.7x51.8x2.6x
Fri, 23 Feb 2024US$128.7bUS$49.0bUS$2.5b29.6x51.8x2.6x
Sun, 21 Jan 2024US$122.5bUS$50.1bUS$2.6b27.1x48x2.4x
Tue, 19 Dec 2023US$127.2bUS$49.9bUS$2.6b27.1x48.3x2.5x
Thu, 16 Nov 2023US$111.3bUS$50.0bUS$2.6b23.3x42.7x2.2x
Sat, 14 Oct 2023US$115.4bUS$50.0bUS$3.3b23.7x35.2x2.3x
Mon, 11 Sep 2023US$129.8bUS$50.0bUS$3.3b19.8x39.6x2.6x
Wed, 09 Aug 2023US$141.3bUS$49.6bUS$3.0b25.8x46.9x2.8x
Fri, 07 Jul 2023US$151.3bUS$49.3bUS$3.1b22.3x48.3x3.1x
Price to Earnings Ratio

48.3x


Total Market Cap: US$151.3bTotal Earnings: US$3.1bTotal Revenue: US$49.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Personal Products Industry Price to Earnings3Y Average 172.8x202420252026
Current Industry PE
  • Investors are pessimistic on the American Personal Products industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 121x which is lower than its 3-year average PE of 173x.
  • The 3-year average PS ratio of 2.1x is higher than the industry's current PS ratio of 1.7x.
Past Earnings Growth
  • The earnings for companies in the Personal Products industry have declined 40% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Consumer Staples industry?

US Market0.31%
Consumer Staples0.80%
Personal Products1.75%
Personal Products1.75%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
KVUE KenvueUS$19.076.8%
+US$2.3b		-8.9%PE22.6x
ELF e.l.f. BeautyUS$69.9110.7%
+US$400.0m		-43.8%PE157.9x
IPAR InterparfumsUS$109.9710.6%
+US$337.9m		-18.2%PE20.8x
BRBR BellRing BrandsUS$12.3821.7%
+US$257.0m		-78.6%PE9.1x
EPC Edgewell Personal CareUS$27.7822.3%
+US$233.2m		18.7%PS0.6x

Latest News

FTLF
US$11.06
FitLife Brands
7D
-6.7%
1Y
-21.8%
COTY
US$1.96
Coty
7D
2.6%
1Y
-57.8%
BRBR
US$12.38
BellRing Brands
7D
21.7%
1Y
-78.6%
EL
US$79.37
Estée Lauder Companies
7D
-6.1%
1Y
-1.8%
Narrative Update • Jun 29

EL: Turnaround Progress And Higher Margins Will Still Pressure Shares

Analysts have trimmed their fair value estimate for Estée Lauder Companies from $74.37 to $70.00, reflecting updated views on a slightly higher discount rate, more moderate revenue growth assumptions, a higher projected profit margin, and a lower future P/E multiple. What's in the News for Estée Lauder Companies Fiscal Q3 2026 earnings for Estée Lauder Companies surpassed expectations, with earnings per share reported 40% above forecasts and revenue supported by double digit fragrance sales growth, according to recent results coverage.
ODD
US$14.29
Oddity Tech
7D
16.1%
1Y
-81.1%
HLF
US$12.79
Herbalife
7D
5.4%
1Y
48.4%
OLPX
US$2.05
Olaplex Holdings
7D
-0.5%
1Y
46.4%
Narrative Update • Jun 26

OLPX: Raised Price Views And Governance Settlement Will Shape Earnings Reassessment

Analysts have raised their price targets on Olaplex Holdings, with one firm increasing its target to $2.00 from $1.40 as they factor in updated assumptions on revenue growth, profit margins and future P/E. These changes support a modestly improved view of the stock's earnings potential.
KVUE
US$19.07
Kenvue
7D
6.8%
1Y
-8.9%
Narrative Update • Jun 24

KVUE: Future Returns Will Balance Kimberly-Clark Deal Timing And Execution Risks

Kenvue's analyst price target has been trimmed by $1 as analysts factor in updated discount rate assumptions and peer commentary that shifts more upside toward related deals in later years. Analyst Commentary Recent commentary around Kenvue highlights a split view, with some analysts focusing on the potential value of its connection to Kimberly-Clark over time, while others are trimming near term expectations and adjusting discount rate assumptions.
PAVS
US$6.15
Paranovus Entertainment Technology
7D
-61.9%
1Y
-99.9%
EPC
US$27.78
Edgewell Personal Care
7D
22.3%
1Y
18.7%
ELF
US$69.91
e.l.f. Beauty
7D
10.7%
1Y
-43.8%
IPAR
US$109.97
Interparfums
7D
10.6%
1Y
-18.2%
Analysis Article • Jun 19

Interparfums (IPAR) Stock Could Be 9.4% Undervalued After Institutional Buying

Interparfums (IPAR) is back in focus after recent data showed institutional investors now hold 66.49% of the company, with largest shareholder Chuck Royce significantly increasing his position last quarter. See our latest analysis for Interparfums. Interparfums’ recent 1 month share price return of 9.77% and 3 month share price return of 10.15%, taking the stock to US$99.09, contrast with a 1 year total shareholder return that declined 22.5%. This suggests improving short term momentum after...
NAGE
US$3.30
Niagen Bioscience
7D
-3.2%
1Y
-77.1%
Narrative Update • Jun 16

NAGE: Injectables And Expanded Clinical Access Will Support Future Buyback Upside

Niagen Bioscience's analyst price target has been reduced by a combined $5 across recent reports as analysts factor in updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples, while maintaining a fair value estimate of $12.60. Analyst Commentary Recent research on Niagen Bioscience highlights a mix of optimism about the company’s long term potential and caution around the assumptions that underpin the current fair value estimate of $12.60.
WALD
US$1.50
Waldencast
7D
-6.8%
1Y
-38.8%
Narrative Update • Jun 15

WALD: Obagi Sale And Injectables Launch Will Support Future Upside

Analysts have lifted their price target on Waldencast stock to $3.00 from $2.50, citing the agreed sale of the Obagi skin care and aesthetics business for up to $460m and the view that current valuation does not fully reflect the strength of Obagi, Milk and the upcoming Saypha injectables launch. Analyst Commentary Bullish analysts see the agreed sale of the Obagi skin care and aesthetics business and the ongoing investment in Saypha injectables as key supports for the recent reset to a $3.00 price target.
BHST
US$2.79
BioHarvest Sciences
7D
-8.5%
1Y
-58.5%